BioSpace News Archive

Synaptive Medical, a global pioneer in automation and robotics, today revealed an automated white matter segmentation feature to augment its ModusTM Plan surgical planning software tool that remains under development.

Dr. Justin Sanchez, a noted expert in neurotechnology and Director of the Biological Technologies Office (BTO) at DARPA, will join Battelle as a Technical Fellow, a prestigious position where he will guide Battelle’s life sciences research business

Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), being held April 29 – May 2, 2019 in Washington D.C.

QxMD Software Inc., a digital learning technology company that makes it easier for healthcare professionals (HCPs) to discover and apply the latest evidence for use in clinical practice, today announced the availability of its newest point-of-care clinical tool ‘International IgA Nephropathy Prediction Tool’ for Calculate by QxMD mobile and web app users.

Nancy Harrison, Chair, LifeSciences BC Board of Directors, announced today the appointment of Wendy Hurlburt, as the organization’s new President and CEO. “We are very pleased to have Wendy join and lead our team; as she brings a strong business background in pharmaceutical, not-for-profit and operations management to this executive position.

Circuit Clinical™ is proud to announce a unique collaboration with Roswell Park Comprehensive Cancer Center, to support the expansion of clinical trial opportunities to its outpatient oncology practices.

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will host two CME-accredited satellite symposia adjunct to the 2019 AUA Annual Meeting

Retrospective analysis showed applying latest International Club of Ascites (ICA) diagnostic criteria would be estimated to result in earlier time to treatment at a lower SCr level and potentially improved outcomes

Zymeworks Inc. announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas.

QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2019 on Monday, May 6 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time.